12788 Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices 

questions is April 19, 2021. 

Applications and other information 

regarding the CDFI Fund and its 

programs may be obtained from the 

CDFI Fund’s website at http://

www.cdfifund.gov. The CDFI Fund will 

post on its website responses to 

questions of general applicability 

regarding the CDFI Bond Guarantee 

Program. 

B. The CDFI Fund’s contact 

information is as follows: 

TABLE 2—CONTACT INFORMATION

Type of question Telephone number 

(not toll free) Email addresses 

CDFI Bond Guarantee Program ........................................................................................ (202) 653–0421 Option 5 bgp@cdfi.treas.gov. 

CDFI Certification ............................................................................................................... (202) 653–0423 ............. ccme@cdfi.treas.gov. 

Certification, Compliance Monitoring and Evaluation ........................................................ (202) 653–0423 ............. ccme@cdfi.treas.gov. 

Information Technology Support ........................................................................................ (202) 653–0422 ............. AMIS@cdfi.treas.gov. 

C. Communication with the CDFI 

Fund. The CDFI Fund will 

communicate with applicants, Qualified 

Issuers, Program Administrators, 

Servicers, Certified CDFIs and Eligible 

CDFIs, using the contact information 

maintained in their respective AMIS 

accounts. Therefore, each such entity 

must maintain accurate contact 

information (including contact person 

and authorized representative, email 

addresses, fax numbers, phone numbers, 

and office addresses) in its respective 

AMIS account. For more information 

about AMIS, please see the AMIS 

Landing Page at https://

amis.cdfifund.gov. 

VII. Information Sessions and Outreach 

The CDFI Fund may conduct 

webcasts, webinars, or information 

sessions for organizations that are 

considering applying to, or are 

interested in learning about, the CDFI 

Bond Guarantee Program. The CDFI 

Fund intends to provide targeted 

outreach to both Qualified Issuer and 

Eligible CDFI participants to clarify the 

roles and requirements under the CDFI 

Bond Guarantee Program. For further 

information, or to sign up for alerts, 

please visit the CDFI Fund’s website at 

http://www.cdfifund.gov. 

Authority: Pub. L. 111–240; 12 U.S.C. 

4701, et seq.; 12 CFR part 1808; 12 CFR part 

1805;12 CFR part 1815. 

Jodie L. Harris, 

Director, Community Development Financial 

Institutions Fund. 

[FR Doc. 2021–04429 Filed 3–3–21; 8:45 am] 

BILLING CODE 4810–70–P 

U.S.-CHINA ECONOMIC AND 

SECURITY REVIEW COMMISSION 

Notice of Open Public Hearing 

AGENCY: U.S.-China Economic and 

Security Review Commission. 

ACTION: Notice of open public hearing. 

SUMMARY: Notice is hereby given of the 

following hearing of the U.S.-China 

Economic and Security Review 

Commission. The Commission is 

mandated by Congress to investigate, 

assess, and report to Congress annually 

on ‘‘the national security implications of 

the economic relationship between the 

United States and the People’s Republic 

of China.’’ Pursuant to this mandate, the 

Commission will hold a public hearing 

in Washington, DC, on March 19, 2021, 

on ‘‘U.S. Investment in China’s Capital 

Markets and Military-Industrial 

Complex.’’ 

DATES: The hearing is scheduled for 

Friday, March 19, 2021, 9:15 a.m. 

ADDRESSES: This hearing will be held 

with panelists and Commissioners 

participating in-person or online via 

videoconference. Members of the 

audience will be able to view a live 

webcast via the Commission’s website at 

www.uscc.gov. Also, please check the 

Commission’s website for possible 

changes to the hearing schedule. 

Reservations are not required to attend 

the hearing. 

FOR FURTHER INFORMATION CONTACT: Any 

member of the public seeking further 

information concerning the hearing 

should contact Jameson Cunningham, 

444 North Capitol Street NW, Suite 602, 

Washington DC 20001; telephone: 202– 

624–1496, or via email at jcunningham@

uscc.gov. Reservations are not required 

to attend the hearing. 

ADA Accessibility: For questions 

about the accessibility of the event or to 

request an accommodation, please 

contact Jameson Cunningham via email 

at jcunningham@uscc.gov. Requests for 

an accommodation should be made as 

soon as possible, and at least five 

business days prior to the event. 

SUPPLEMENTARY INFORMATION: 

Background: This is the third public 

hearing the Commission will hold 

during its 2021 report cycle. The 

hearing will examine the Chinese 

government’s use of capital markets to 

advance its technology and defense 

capabilities and evaluate the risks of 

U.S. investors’ capital being leveraged 

for such ends. The opening panel will 

examine the evolving role of the state in 

China’s capital markets, including the 

Chinese Communist Party’s 

involvement in corporate governance. 

The second panel will review China’s 

financial opening and U.S. and foreign 

investor participation in China’s capital 

markets. The third panel will assess 

U.S. national security risks posed by 

investment in Chinese companies. The 

fourth panel will evaluate U.S. legal 

authority and current restrictions on 

outbound investment to China’s capital 

markets. 

The hearing will be co-chaired by 

Commissioner Robert Borochoff and 

Commissioner Jeffrey Fiedler. Any 

interested party may file a written 

statement by March 19, 2021 by 

transmitting to the contact above. A 

portion of the hearing will include a 

question and answer period between the 

Commissioners and the witnesses. 

Authority: Congress created the U.S.-China 

Economic and Security Review Commission 

in 2000 in the National Defense 

Authorization Act (Pub. L. 106–398), as 

amended by Division P of the Consolidated 

Appropriations Resolution, 2003 (Pub. L. 

108–7), as amended by Public Law 109–108 

(November 22, 2005), as amended by Public 

Law 113–291 (December 19, 2014). 

Dated: March 1, 2021. 

Daniel W. Peck, 

Executive Director, U.S.-China Economic and 

Security Review Commission. 

[FR Doc. 2021–04507 Filed 3–3–21; 8:45 am] 

BILLING CODE 1137–00–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Tiered Pharmacy Copayments for 

Medications; Calendar Year 2021 

Update 

AGENCY: Department of Veterans Affairs. 

ACTION: Notice. 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices 12789 

SUMMARY: This Department of Veterans 

Affairs (VA) Notice updates the 

information on Tier 1 medications. 

FOR FURTHER INFORMATION CONTACT: 

Joseph Duran, Office of Community 

Care, Veterans Health Administration, 

Department of Veterans Affairs, 810 

Vermont Avenue NW, Washington, DC 

20420; Joseph.Duran2@va.gov; 303– 

370–1637. This is not a toll-free number. 

SUPPLEMENTARY INFORMATION: Section 

17.110 of title 38, CFR, governs 

copayments for medications that VA 

provides to veterans. Section 17.110 

provides the methodologies for 

establishing the copayment amount for 

each 30-day or less supply of 

medication provided by VA on an 

outpatient basis (other than medication 

administered during treatment). 

Tier 1 medication means a multisource medication that has been 

identified using the process described in 

paragraph (b)(2) of this section. Not less 

than once per year, VA will identify a 

subset of multi-source medications as 

Tier 1 medications. Only medications 

that meet all of the criteria in 38 CFR 

17.110(b)(2)(i), (ii), and (iii) will be 

eligible to be considered Tier 1 

medications, and only those 

medications that meet all of the criteria 

in paragraph (b)(2)(i) of this section will 

be assessed using the criteria in 

paragraphs (b)(2)(ii) and (iii). 

Based on the methodologies set forth 

in § 17.110, this notice updates the list 

of Tier 1 medications for Calendar Year 

2021. The Tier 1 medication list is 

posted on VA’s Community Care 

website at the following link: https://

www.va.gov/COMMUNITYCARE/ 

revenue_ops/copays.asp under the 

heading ‘‘Tier 1 Copay Medication 

List.’’ 

The following table is the Tier 1 

Copay Medication List that is effective 

January 1, 2021 and will remain in 

effect until December 31, 2021. 

Condition VA product name 

Arthritis and Pain ................................................. Aspirin Buffered Tablet. 

Aspirin Chewable Tablet. 

Aspirin Enteric Coated Tablet. 

Allopurinol Tablet. 

Celecoxib Capsule. 

Diclofenac Tablet. 

Ibuprofen Tablet. 

Meloxicam Tablet. 

Naproxen Tablet. 

Blood Thinners and Platelet Inhibitors ................ Clopidogrel Bisulfate Tablet. 

Warfarin Sodium Tablet. 

Bone Health ........................................................ Alendronate Tablet. 

Cholesterol .......................................................... Atorvastatin Tablet. 

Ezetimibe Tablet. 

Pravastatin Tablet. 

Rosuvastatin Calcium Tablet. 

Simvastatin Tablet. 

Dementia ............................................................. Donepezil Tablet. 

Diabetes .............................................................. Glimepiride Tablet. 

Glipizide Tablet. 

Metformin Hydrochloride (HCL) Tablet. 

Metformin HCL 24-Hour Sustained Action (SA) Tablet. 

Pioglitazone HCL Tablet. 

Electrolyte Supplement ....................................... Potassium SA Tablet. 

Potassium SA dispersible Tablet. 

Gastrointestinal Health ........................................ Famotidine Tablet. 

Omeprazole Enteric Coated (EC) Capsule. 

Pantoprazole Sodium EC Capsule. 

Glaucoma and Eye Care ..................................... Diclofenac Solution. 

Dorzolamide 2%/Timolol 0.5% Solution. 

Latanoprost 0.005% Solution. 

Polyethylene Glycol 400/Polyethylene Glycol 4000 Solution. 

Carboxymethylcellulose Sodium Solution. 

Heart Health and Blood Pressure ....................... Amlodipine Tablet. 

Amiodarone HCL Tablet. 

Aspirin (see Arthritis and Pain). 

Atenolol Tablet. 

Carvedilol Tablet. 

ChlorthalidoneTablet. 

Clonidine Tablet. 

Diltiazem 24-Hour Capsule. 

Diltiazem HCL Tablet. 

Enalapril Maleate Tablet. 

Furosemide Tablet. 

Hydralazine HCL Tablet. 

Hydrochlorothiazide Tablet/Capsule. 

Hydrochlorothiazide/Lisinopril Tablet. 

Hydrochlorothiazide/Losartan Tablet. 

Hydrochlorothiazide/Triamterene Tablet/Capsule. 

Isosorbide Mononitrate SA Tablet. 

Lisinopril Tablet. 

Losartan Tablet. 

Metoprolol Succinate SA Tablet. 

Metoprolol Tartrate Tablet. 

Nifedipine SA Capsule. 


jbell on DSKJLSW7X2PROD with NOTICES
12790 Federal Register / Vol. 86, No. 41 / Thursday, March 4, 2021 / Notices 

Condition VA product name 

Nitroglycerin sublingual Tablet. 

Prazosin HCL Capsule. 

Propranolol HCL Tablet. 

Spironolactone Tablet. 

Mental Health ...................................................... Amitriptyline HCL Tablet. 

Buspirone HCL Tablet. 

Bupropion HCL Tablet. 

Bupropion HCL SA (12HR–SR) Tablet. 

Bupropion HCL SA (24HR–XL) Tablet. 

Citalopram Hydrobromide Tablet. 

Duloxetine HCL EC Capsule. 

Escitalopram Oxalate Tablet. 

Fluoxetine Tablet/Capsule. 

Mirtazapine Tablet. 

Paroxetine Tablet. 

Sertraline HCL Tablet. 

Trazodone Tablet. 

Venlafaxine HCL Immediate (IR) Tablet. 

Venlafaxine HCL SA Capsule. 

Respiratory Condition .......................................... Montelukast NA Tablet. 

Seizures .............................................................. Gabapentin Capsule. 

Lamotrigine Tablet. 

Topiramate Tablet. 

Thyroid Conditions .............................................. Levothyroxine Sodium Tablet. 

Urologic (Bladder and Prostate) Health .............. Alfuzosin HCL SA Tablet. 

Doxazosin Mesylate Tablet. 

Finasteride Tablet. 

Oxybutynin Chloride IR Tablet. 

Oxybutynin Chloride SA Tablet. 

Sildenafil Tablet. 

Tamsulosin HCL Capsule. 

Terazosin HCL Capsule. 

Signing Authority 

Denis McDonough, Secretary of 

Veterans Affairs, approved this 

document on February 26, 2021, and 

authorized the undersigned to sign and 

submit the document to the Office of the 

Federal Register for publication 

electronically as an official document of 

the Department of Veterans Affairs. 

Luvenia Potts, 

Regulation Development Coordinator, Office 

of Regulation Policy & Management, Office 

of the Secretary, Department of Veterans 

Affairs. 

[FR Doc. 2021–04458 Filed 3–3–21; 8:45 am] 

BILLING CODE 8320–01–P 


jbell on DSKJLSW7X2PROD with NOTICES